<?xml version='1.0' encoding='utf-8'?>
<document id="23729226"><sentence text="Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone."><entity charOffset="93-102" id="DDI-PubMed.23729226.s1.e0" text="midazolam" /><entity charOffset="104-116" id="DDI-PubMed.23729226.s1.e1" text="erythromycin" /><entity charOffset="122-135" id="DDI-PubMed.23729226.s1.e2" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.23729226.s1.e0" e2="DDI-PubMed.23729226.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23729226.s1.e0" e2="DDI-PubMed.23729226.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23729226.s1.e0" e2="DDI-PubMed.23729226.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23729226.s1.e1" e2="DDI-PubMed.23729226.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23729226.s1.e1" e2="DDI-PubMed.23729226.s1.e2" /></sentence><sentence text="Netupitant is a new highly selective neurokinin-1 receptor antagonist being studied for the prevention of nausea and vomiting in patients undergoing chemotherapy" /><sentence text=" In vitro studies suggest that netupitant inhibits the cytochrome P-450 isoenzyme 3A4 (CYP3A4)" /><sentence text=" Because netupitant may be used with a variety of drugs, which may be substrates of CYP3A4, two studies were designed to establish the potential risk for drug-drug interaction with three different CYP3A4 substrates: midazolam, erythromycin, and dexamethasone"><entity charOffset="216-225" id="DDI-PubMed.23729226.s4.e0" text="midazolam" /><entity charOffset="227-239" id="DDI-PubMed.23729226.s4.e1" text="erythromycin" /><entity charOffset="245-258" id="DDI-PubMed.23729226.s4.e2" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.23729226.s4.e0" e2="DDI-PubMed.23729226.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23729226.s4.e0" e2="DDI-PubMed.23729226.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23729226.s4.e0" e2="DDI-PubMed.23729226.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23729226.s4.e1" e2="DDI-PubMed.23729226.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23729226.s4.e1" e2="DDI-PubMed.23729226.s4.e2" /></sentence><sentence text="" /><sentence text="Both trials were three-period crossover studies performed in healthy subjects" /><sentence text=" In the first study, 20 subjects received netupitant and either midazolam or erythromycin"><entity charOffset="64-73" id="DDI-PubMed.23729226.s7.e0" text="midazolam" /><entity charOffset="77-89" id="DDI-PubMed.23729226.s7.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.23729226.s7.e0" e2="DDI-PubMed.23729226.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23729226.s7.e0" e2="DDI-PubMed.23729226.s7.e1" /></sentence><sentence text=" In the second study, 25 subjects received netupitant and dexamethasone"><entity charOffset="43-53" id="DDI-PubMed.23729226.s8.e0" text="netupitant" /><entity charOffset="58-71" id="DDI-PubMed.23729226.s8.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.23729226.s8.e0" e2="DDI-PubMed.23729226.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23729226.s8.e0" e2="DDI-PubMed.23729226.s8.e1" /></sentence><sentence text=" Serial blood samples were collected over the course of the two studies and pharmacokinetic parameters were determined for all analytes" /><sentence text="" /><sentence text="Netupitant, by inhibiting the CYP3A4, increased the C max and AUCinf of midazolam by 40 and 144 %, respectively, and the C max and AUCinf of erythromycin by 30 %"><entity charOffset="141-153" id="DDI-PubMed.23729226.s11.e0" text="erythromycin" /></sentence><sentence text=" Netupitant was shown to increase the exposure to dexamethasone in a dose-dependent manner with the mean increase in AUC and C max by 72 and 11 %, respectively, on day 1 and by 138 and 75 %, respectively, on day 4 when co-administered with 300 mg of netupitant"><entity charOffset="50-63" id="DDI-PubMed.23729226.s12.e0" text="dexamethasone" /><entity charOffset="250-260" id="DDI-PubMed.23729226.s12.e1" text="netupitant" /><pair ddi="false" e1="DDI-PubMed.23729226.s12.e0" e2="DDI-PubMed.23729226.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23729226.s12.e0" e2="DDI-PubMed.23729226.s12.e1" /></sentence><sentence text="" /><sentence text="The results of these studies suggest that netupitant is a moderate inhibitor of CYP3A4 and therefore, co-administration with drugs that are substrates of CYP3A4 may require dose adjustments" /><sentence text=" Treatments were well tolerated in both studies" /><sentence text="" /></document>